Tissue-nonspecific alkaline phosphatase (TNAP) is a ubiquitous enzyme expressed at high levels in bone, liver, and kidney. It appears involved in dephosphorylation of numerous phosphate monoesters, but only 2 of them, pyrophosphate and pyridoxal phosphate, have yet been unequivocally documented. Discovery and characterization of other substrates could be considerably facilitated if specific and potent modulators of TNAP activity with various modes of action were available. Here, the authors describe in detail a high-throughput screening campaign to identify inhibitors of TNAP, performed within the Molecular Library Screening Center Network (MLSCN). A novel homogeneous luminescent TNAP assay was developed and optimized with respect to the enzyme and substrate concentrations, enabling identification of a large number of compounds overlooked by a conventional colorimetric assay. Several new chemical series were identified from screening the Molecular Libraries Small Molecule Repository (MLSMR) collection and demonstrated to have diverse selectivity and mode of inhibition profiles. The nanomolar potency of some of these scaffolds surpasses currently known inhibitors. This article provides an example of a success where the Roadmap Initiative collaborative model, sponsored by the National Institutes of Health, brought together a deep knowledge of target biology from a principal investigator's laboratory, a well-designed compound collection from the MLSMR, and an industrial-level screening facility and staff at the MLSCN center to identify pharmacologically active compounds, with outstanding selectivity data from a panel of more than 200 publicly accessible assays, through a high-throughput screen. (Journal of Biomolecular Screening 2009:824-837) 
INTRODUCTION
A lkaline phosphatases (e.C.3.1.3.1) (aps) are dimeriC enzymes, present in most organisms, 1 where they catalyze the hydrolysis of phosphomonoesters. Although the family of alkaline phosphatases has been known for many decades, the full spectrum of their biological activities is not fully understood; for some of the family members, they are postulated, and for others, they are yet unknown. In humans, 3 of the 4 isozymes are tissue specific: intestinal (IAP), placental (PLAP), and germ cell (GCAP) APs. The fourth AP is tissue nonspecific (TNAP) and is expressed in bone, liver, and kidney. 2 It is capable of dephosphorylating a number of substrates in vitro, yet biological relevance of most of these activities is not known. Recent studies provide compelling proof that in bone tissue, TNAP ensures normal bone mineralization by hydrolyzing extracellular inorganic pyrophosphate, PP i , a potent inhibitor of hydroxyapatite formation at concentrations normally found in plasma. [3] [4] [5] PP i prevents calcification of rat aortas in culture 6 and in vitamin D-toxic rats in vivo. 7 Humans with low levels of PP i due to the absence of the PP i -producing enzyme ectonucleotide pyrophosphatase/phosphodiesterases-1 (NPP1, aka PC-1) develop severe, fatal arterial calcification. [8] [9] [10] [11] Humans undergoing chronic hemodialysis have reduced plasma levels of PP i and commonly have arterial calcification. 12 Thus, there are compelling data that PP i is an important endogenous mineralization inhibitor of medial vascular calcification. Normalization of PP i levels in NPP1 null and ANKdeficient mice improves their soft tissue ossification abnormalities. 13, 14 Therefore, TNAP may be a useful therapeutic target for the treatment of arterial calcification. Indeed, substantial evidence points to the presence of TNAP-rich vesicles at sites of mineralization in human arteries. The presence of TNAP-enriched matrix vesicles (MVs) in human ath-erosclerotic lesions suggests an active role in the promotion of the accompanying vascular calcification. [15] [16] [17] Increased expression of TNAP accelerates calcification by bovine vascular smooth muscle cells (VSMCs), 18 and macrophages can induce a calcifying phenotype in human VSMCs by activating TNAP in the presence of interferon gamma (IFNγ) and 1,25(OH) 2 D3. 19 Recently, we have shown upregulation of TNAP activity in Enpp1 -/and ank/ank VSMCs 20 and in the aortas of uremic rats, 21 and we have shown that the pharmacological downregulation of this upregulated TNAP activity suppresses VSMC-dependent calcification. 20 Thus, there is ample evidence warranting exploration of the therapeutic potential of TNAP inhibition at sites of arterial calcification to increase local concentration of PP i , thereby reducing inappropriate mineralization. On the other hand, TNAP expression pattern suggests that it is most likely involved in dephosphorylation of other substrates defined by its location. Unfortunately, the identity of these substrates has yet to be established. Discovery of potent and specific TNAP inhibitors would facilitate these explorations by providing tools for TNAP activity knockdown selective to the substrates' nature and concentrations.
The molecular mechanism of the AP catalytic reaction is common to the enzyme from various species and tissues 22 and is depicted in Figure 1 . The initial reaction catalyzed by AP (designated as E in the figure) consists of a phosphate donor substrate (DO-P i ) binding step, phosphate-moiety transfer to the active site Ser, and first product alcohol (DOH) release. In the second part of the reaction, the second product phosphate is released through hydrolysis of the covalent intermediate (E-P i ) and dissociation of inorganic phosphate from the noncovalent complex (E⋅P i ). Depending on the origin of the enzyme and the exact conditions of the reaction, either hydrolysis of E-P i or release of the phosphate from E⋅P i is rate limiting, resulting in the enzyme being kinetically "trapped" in these enzyme-P i forms. However, in the presence of some amine-containing alcohols (AOH), phosphate is preferentially released from enzyme via transphosphorylation reaction, yielding phosphorylated amino alcohols. This path provides >100-fold acceleration to the phosphate release. Thus, amine-containing alcohols serve as the second substrate molecule in the Ping Pong Bi Bi mechanism of AP reaction substituting inefficient substrate water. AP assays commonly used in clinical practice 23 are based on dephosphorylation of p-nitrophenol phosphate (pNPP) in the presence of a high concentration of amine-alcohol-containing buffers, such as 2-amino-2-methyl-1-propanol and diethanolamine (DEA). Besides maintaining an alkaline pH, the buffer also provides saturating levels of phosphate acceptor substrate for the AP transphosphorylation reaction necessary for boosting the assay sensitivity. Interestingly, the biological significance of AOH is still unknown, and it is unclear if any biological molecule is capable of performing the function of AOH in vivo.
TNAP, like all mammalian APs, is inhibited uncompetitively by a number of small-molecule compounds. Uncompetitive inhibitors bind only to the enzyme-substrate (ES) complex and therefore cannot be overcome by high substrate concentrations and indeed work best when enzyme is saturated with the substrate. They include L-homoarginine, 24 as well as some unrelated compounds, such as levamisole 25 and theophylline. 26 However, these known inhibitors of TNAP are not entirely specific for this AP isozyme, have low affinity, and are not particularly effective at inhibiting the pyrophosphatase activity of TNAP. For these reasons, we initiated a comprehensive effort to screen for and optimize, via structure-activity and medicinal chemistry efforts, novel potent TNAP inhibitors that are capable of specifically inhibiting diverse activities of TNAP.
This article documents a successful screening campaign that led to the identification of potent small-molecule TNAP inhibitors. In the scope of this campaign, a novel TNAP assay was developed and optimized to ensure optimal sensitivity in detecting ligands with different modes of action (MOA), which is achieved at concentrations of both substrates equal to their Michaelis constants (K m ) values. Subsequent high-throughput screening (HTS) and follow-up studies led to identification of several potent and selective inhibitory scaffolds targeting TNAP but not related enzymes and exhibiting diverse biochemical properties and MOA.
Catalytic mechanism of alkaline phosphatase reaction (see Holtz et al. 22 ). E, alkaline phosphatase enzyme molecule; DO-P i , substrate molecule; E-P i , phosphorenzyme (enzyme phosphorylated on Ser-93 in the TNAP sequence of its active site); DOH, product alcohol; E⋅Pi, noncovalent complex of inorganic phosphate in the active site; AOH, an alcohol molecule, acceptor substrate of transphosphorylation reaction acceptor; AO-P i , product of transphosphorylation reaction.
MATERIALS AND METHODS

Reagents
The CDP-star substrate (2-chloro-5-(4-methoxyspiro{1,2dioxetane-3,2′(5′-chloro)-tricyclo [3.3.1.13.7]decan}-4-yl)-1phenyl phosphate disodium salt; CAS 160081-61-9) was obtained from New England Biolabs (Ipswich, MA). All other chemicals were of an analytical grade.
Compound collection used in HTS
The compound library was supplied by the National Institutes of Health (NIH) Molecular Libraries Small Molecule Repository (MLSMR, http://www.mli.nih.gov/mlsmr). The MLSMR, funded by the NIH, is responsible for the selection of small molecules for HTS screening, their purchase and quality control (QC) analysis, library maintenance, and distribution within the NIH Molecular Libraries Screening Center Network (MLSCN, http://www.mli.nih.gov/mlscn). Both MLSMR and MLSCN are parts of the Molecular Libraries Initiatives (MLI, http://nihroadmap.nih.gov/molecularlibraries) under the NIH Roadmap Initiatives (www.nihroadmap.nih.gov). MLSMR compounds are acquired from commercial and in part from academic and government sources and are selected based on the following criteria: samples are available for resupply in 10-mg quantity, are at least 90% pure, have acceptable physicochemical properties, and contain no functional groups or moieties that are known to generate artifacts in HTS (http:// mlsmr.glpg.com/). Compounds are selected to represent diversified chemical space with clusters of closely related analogs around them to aid in the HTS-based structure-activity relationship (SAR) analysis.
Expression and preparation of test enzymes
Expression plasmids containing a secreted epitope-tagged TNAP were transfected into COS-1 cells for transient expression. 27 The medium was replaced with Opti-MEM 24 h later, and the serum-free media containing secreted proteins were collected 60 h after electroporation. The conditioned medium was dialyzed against Tris-buffered saline (TBS) containing 1 mM MgCl 2 and 20 mM ZnCl 2 (to remove phosphate) and filtered through a 0.22-µm cellulose acetate filter.
HTS assays
Development of the novel luminescent TNAP assay using CDP-star substrate and detailed protocol of its application for HTS is described in more detail elsewhere. 28 Briefly, the assay was performed in 384-well white plates (784075, Greiner, Monroe, NC) at 50 µM CDP-star substrate in assay buffer containing 100 mM DEA-HCl (pH 9.8), 1 mM MgCl 2 , and 20 µM ZnCl 2 . The luminescence signal was measured after a 30-min incubation at room temperature on an EnVision plate reader (PerkinElmer, Waltham, MA). Analogous luminescent assays were optimized and used for PLAP and IAP with the CDP-star concentration adjusted to their respective K m values, 85 µM and 177 µM, respectively.
The colorimetric TNAP assay was performed as previously described 20 with slight modifications. TNAP in assay buffer containing 1M DEA-HCl (pH 9.8), 1 mM MgCl 2 , and 20 uM ZnCl 2 was added with 0.5 mM pNPP substrate, and after a 1-h incubation, the reaction was terminated by adding 2,3-dimercapto-1-propanesulfonate (a compound that binds Zn 2+ with high affinity, thus inactivating the enzyme) to 100 µM. TNAP activity was measured using absorbance at 405 nm (OD 405 assay) or at 620 nm after addition of malachite green-based phosphate detection reagent (MG assay) prepared according to a published procedure. 29 Compound solubility was measured on a NEPHELOstar plate reader (BMG Labtech, Offenburg, Germany) that measures the intensity of light scattered by compound solution to detect potential compound precipitation. Compound concentrations for which the signal in the well was higher than an average value of the control wells by >3-fold the standard deviation were assumed to have precipitate and excluded from doseresponse data analysis.
HTS and hit confirmation
Primary TNAP screening was completed on MLSMR 64,394 compounds using the luminescent assay at a single concentration of 20 µM. Levamisole at 1 mM concentration was used as positive control. Z′ factor was calculated according to a published formula. 30 Compound efficacy was estimated after data conversion to percent inhibition using equation (1):
where NC and PC represent average values of plate negative and positive control wells, respectively, and Y is a value observed in a well with the tested compound. Compounds exhibiting greater than 50% inhibition of TNAP at this concentration were defined as primary positives; the selection of 50% inhibition cutoff followed pragmatic considerations and in all the cases exceeded the 3-sigma statistical limit. The primary positives were confirmed in single-concentration and doseresponse inhibition studies; each dose-response test was performed using duplicate 10-point curves with 2-fold compound serial dilution. The data were analyzed using Cbis software (ChemInnovation, San Diego, CA). Initially, dose-response data were fitted to the Hill equation (equation (2)) according to nonlinear regression:
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where [C] is compound concentration in micromolar (µM) units, IC 50 is the concentration value of half-maximal inhibition, and n H is the Hill coefficient of the curve. For mode of inhibition (MOI) studies, the compounds efficacy was tested in the presence of several concentrations of CDP-star or DEA and analyzed using Prism 4.03 (GraphPad Software, San Diego, CA); the data were fitted to an equation describing a hyperbolic curve (equation (3)):
Hit clustering
A relocation method based on maximal dissimilarity partitioning provided in the Accelrys Pipeline Pilot's Chemistry Component was used for clustering of the hit molecules (http://accelrys.com/ products/scitegic/component-collections/chemistry.html).
RESULTS
HTS
The project was originally submitted into MLSCN as an X01 grant. It employed a variation of a clinical AP test 23 that is based on a colorimetric detection of AP activity using pNPP as the chromogenic substrate in the presence of a saturating concentration of phosphate acceptor substrate DEA. The assay yielded robust performance and reproducibility during HTS implementation. However, after screening 20,500 MLSCN compounds using p-nitrophenol detection (see PubChem AID 615) or malachite green-based phosphate detection assay (see PubChem AID 614), we obtained no hits whatsoever. Taking this into consideration, we decided to switch to the luminescent assay that we recently developed for confirmation purposes and use it as the primary HTS assay.
A detailed description of the development and utilization of the novel luminescent HTS assay for TNAP is described elsewhere. 28 Briefly, the assay was optimized to enable screening TNAP in the presence of phosphate-donor and phosphate-acceptor substrates present at their respective K m values. TNAP was screened against the MLSMR collection containing 64,394 compounds. The average Z′ factor for the full screen was equal to 0.82 (range, 0.75-0.89), and every plate was therefore acceptable. Figure 2 presents the histogram and scatterplots of the primary screening data.
From the primary screen, 73 primary positives, compounds causing >50% inhibition, were identified, resulting in a 0.11% hit rate. For initial hit confirmation, aliquots for all the primary positives were obtained from the MLSMR, and the compounds were tested in quadruplicate at the concentration used in primary screening. Hits were similarly tested in the 2 colorimetric assays (see Materials and Methods), OD 405 (pNPP) and MG (malachite green). Surprisingly, only 4 hits were confirmed in either colorimetric assay ( Fig. 3C [pNPP] and 3D [MG]), whereas 55 of the primary hits were reconfirmed in the primary HTS luminescent assay (Fig. 3A) . Because TNAP activity with pNPP substrate and the sensitivity of the detection used there are quite low, 1M DEA (roughly 10 × K m ) is used to accelerate the turnover rate. In contrast, the luminescent assay is extremely sensitive and could easily be performed in the absence of DEA; however, for the purposes of this HTS project, the concentration of DEA was kept at its apparent K m value equal to 0.1M. 28 Therefore, to address the apparent discrepancy in hit confirmation, we also tested the 73 active compounds in the luminescent assay, performed in the presence of 1M DEA-based buffer similar to the colorimetric assays. As can be seen in Figure 3B , the number of hits significantly decreased and matched the hit rate of the colorimetric assays, suggesting that a high DEA concentration interferes with the binding of most of the hits, perhaps through a direct competition for the binding site.
An additional observation from Figure 3B -D is that 2 compounds (in rows E and I) display somewhat higher activity in the high-DEA luminescent assay compared with their activity in the colorimetric assays, which is potentially explained through interference with the luminescent assay. Early on in the project, we developed and implemented a luminescent counterscreen using PLAP. This assay served 2 purposes: (1) it detected compounds that have the potential to interfere with the CDP-star-based luminescent assay detection system, and (2) it provided a measure of the specificity of the compounds in the family of APs. The 2 compounds mentioned above indeed inhibited PLAP and were not followed any further.
Full dose-response analysis of 73 primary HTS hits was performed with the luminescent-based assay at 0.1M DEA, and 53 compounds were confirmed as hits that gave IC 50 values below 20 µM ranging from micromolar to submicromolar. The results of the HTS campaign are summarized in Table 1 . Protocol and experimental data for TNAP luminescent-based screening are described in PubChem AID 518.
Primary HTS data analysis
The 53 confirmed hit molecules were clustered into 4 scaffold groups (see Fig. 4 ) and several singletons using Chemistry Component Pipeline Pilot Software (Accelrys, San Diego, CA). Expanded HTS data analysis in relation to the hits was performed on 3 scaffolds (I, II, and III in Fig. 4) , each possessing members with submicromolar potency; the scaffold IV was not further analyzed in this study.
Biarylsulfonamides (scaffold I).
For the biarylsulfonamide scaffold (I in Fig. 4 ) series, the 3 most active compounds of the 4 hits shown in Table 2 share high similarity to each other: all have a 3-amino-substituted pyridine or quinoline moiety and an alkoxy group at the ortho position of the sulfonylbenzene. Although the fourth weaker compound lacked the pyridine moiety, it still contained the o-alkoxy group. We hypothesized that both pyridine and o-alkoxy-substituted sulfonylbenzene are necessary for strong potency in this scaffold. To confirm this, we further "mined" the complete HTS data. Of the 972 molecules belonging to the biarylsulfonamide scaffold ( Fig. 5) , 59 molecules contained o-alkoxy-substituted sulfonylbenzenes, yet only 4 of these (shown in Table 2 ) were active. Of the 972 biarylsulfonamides, 21 contained a pyridine/quinoline moiety, and only 3 of these were active. The 3 strongest actives are indeed in the overlap between these 2 sets ( Fig. 5) , confirming that both a pyridine/quinoline moiety and an o-alkoxy-sulfonylbenzene are required for strong biarylsulfonamide activity.
Pyrazole series (scaffold II). The available data did not suggest immediately which aryl group or R group is preferred for scaffold II (Fig. 4) . However, a similar HTS data analysis was performed to investigate the role of the N and NH pair of the pyrazole ring and the effect of substitution at position 4 of the pyrazole ring in scaffold II ( Table 3 ). There were 5 molecules with a substituent at position 4, and none of them was active in the HTS assay, suggesting that an unsubstituted position 4 of the pyrazole ring is preferred for TNAP inhibition. Other 5-membered ring molecules that lack the N-NH pair did not substitute for the pyrazole ring because 10 molecules in this category were all inactive.
Triazole series (scaffold III). Most of the triazole derivatives (scaffold III in Fig. 4 ) identified in primary screening belong to a more specific subseries, thio-phenyl-triazole ( Fig. 6A) , resembling the ones identified in a previous screening effort. 20 Another triazole derivative (Fig. 6B) was the most potent in the series and was identified as a singleton. Interesting observation: the only biarylsulfonamide compound that lacked a pyridine moiety yet displayed some activity (MLS-0043574 in Table 2 ) also contained a triazole moiety. It is possible that its activity is a product of contribution from structural elements of both scaffolds. 
Hit confirmation
All 53 compounds identified and confirmed as positive inhibitors of TNAP originated from commercial sources. This significantly simplified compound structure verification and potency confirmation was performed on fresh solid compounds. The representatives of the major scaffolds were purchased from their original vendors. Table 4 summarizes the reconfirmation results for lead compounds of each scaffold, and it is notable that potency values from fresh solids (SAR IC 50 values in Table 4 ) closely match those obtained from fresh solutions provided by the MLSMR (HTS IC 50 values).
We purchased and tested 46, 29, and 10 commercially available analogs of the biarylsulfonamide, pyrazole, and triazole series, respectively. These analogs offered confirmation for the SAR conclusions drawn from HTS. Extended SAR studies for these scaffolds are described elsewhere. 31 Furthermore, all the hits were also tested in the luminescent and the colorimetric assay. Three biarylsulfonamides (2 shown in Table 4 ) and a single representative of the pyrazole scaffold, MLS-0039961 (Table 4 and Figure 7) , were the only compounds that demonstrated similar activity in both assays; all other primary positives were inactive in the colorimetric assay. Interestingly, all the hits demonstrated close to perfect hyperbolic dose-response curves; accordingly, for the analysis of the data from this and further experiments, we used a Michaelis-Menten-type equation (equation (3)), compatible with MOI studies.
Exploratory studies on the mechanism of inhibition of the leading scaffolds
Exploratory mechanistic substrate-competition studies were done to elucidate the discrepant inhibitory activity of compounds between the luminescent and colorimetric assays. The most potent compounds from each series-MLS-0038949, MLS-0005718, and MLS-0067142-were selected. The pyrazole MLS-0039961, active in the colorimetric assay, was also added. Data from multiple experiments analyzed according to equation (3) are compiled in Table 5 .
Competition studies with respect to CDP-star ( Table 5 ) suggest that compounds MLS-0005718, MLS-0039961, and MLS-0067142 are competitive with CDP-star as their potency decreased in the presence of increasing concentrations of CDP-star. Interestingly, MLS-0038949 was unique and showed an inverse behavior of increased potency at higher substrate concentrations, consistent with uncompetitive inhibition. DEA variation studies showed that MLS-0005718 and MLS-0067142 inhibition was strongly affected by DEA, consistent with a competitive mechanism ( Table 5 ). In contrast, inhibition by MLS-0038949 and MLS-0039961 was virtually identical at all 3 DEA concentrations tested, suggesting these were noncompetitive inhibitors.
Selectivity of primary actives against other phosphatases
As mentioned above, the PLAP selectivity assay was implemented as an integral part of the hit optimization process. For lead characterization, we added a luminescent assay for IAP to the selectivity panel. The selectivity data for the best representatives of the scaffolds obtained at our screening center (San Diego Center for Chemical Genomics [SDCCG]) and extracted from the PubChem database are summarized in Table 6 . Biarylsulfonamide scaffold compounds did not inhibit PLAP or IAP and were inactive against more than 200 assays in PubChem. Both pyrazole compounds did not inhibit PLAP and had reasonable selectivity against IAP, whereas the triazole compound was equipotent against TNAP and IAP although slightly less potent against PLAP.
DISCUSSION
MLSCN project for screening TNAP
The TNAP screening project completed within the MLSCN was funded through the NIH Roadmap Initiatives (http://nihroadmap.nih.gov) for accelerated discovery of small-molecule tools for basic research. 32 The project was carried out by the SDCCG (http://sdccg.burnham.org), a member of this network, in collaboration with a Burnham laboratory specializing in TNAP-related research. The main goal of the project was to identify potent and selective small-molecule chemical probes that could be used as research tools for understanding the significance of TNAP's physiological and pathological roles. In addition, active compounds were to be tested for their efficacy in biologically relevant model systems and might serve as starting points for the development of therapeutic agents to treat soft tissue calcification. Although the TNAP enzyme has been known for many decades, its participation in diverse biological processes is still being actively investigated. 2 Many phosphate derivatives have been documented as substrates of TNAP-that is, pNPP, α-naphthylphosphate, β-glycerophosphate, phosphoserine, PP i , pyridoxal-5′-phosphate (PLP), phosphothreonine, phosphotyrosine, phosphatides, polyphosphates, adenosine triphosphate (ATP), adenosine diphosphate (ADP), AMP, glucose-1-phosphate, glucose-6-phosphate, fructose-6-phosphate, and others. 2, 33 However, only 2, PP i and PLP, have been unequivocally confirmed as physiological substrates of TNAP because abnormalities in their metabolism explain the phenotypic changes observed in hypophosphatasia, a genetic disease resulting from TNAP deficiency. [34] [35] [36] Furthermore, the role of TNAP in maintaining proper concentrations of extracellular PP i is further documented by the association of low PP i and high TNAP in the vasculature in diverse models of arterial calcification. 20, 21 The in vitro TNAP reaction is dramatically accelerated by amino-containing alcohols acting as phosphate-acceptor substrates for transphosphorylation 28 to overcome the rate-limiting phosphate release from the enzyme. The physiological role of transphosphorylation coupled to TNAP activity or whether relevant endogenous phosphate-acceptor substrates exist in vivo is unknown. Thus, there is an unmet need for a broad assortment of small-molecule chemical probes capable of interrogating the diversity of TNAPs functions and binding sites, as well as deciphering their functions and interactions with potential endogenous phosphate acceptors. To aid in the identification of the chemical probes with diverse mechanisms of action, we have developed a novel homogeneous assay for TNAP with an inherently high signal intensity, sensitivity, and wide dynamic response for both phosphate donor substrates and canonical phosphate acceptors. This approach provided the 
Luminescent assay for TNAP
The development of a novel assay 28 was a critical step in the successful HTS campaign for the identification of these new TNAP inhibitors. This assay was more sensitive and automationfriendly than the commonly used colorimetric assay. 20 The signal (light intensity) of the chemiluminescent reaction is directly proportional to the steady-state rate of the TNAP reaction and is stable for more than 5 h; therefore, measuring the activity of the enzyme does not require termination of the reaction and can be reliably performed in real time. The assay reagents are stable for several days at room temperature, enabling flexible scheduling and automation of the screening. The developed assay was very robust and reproducible, as shown by an average Z′ factor value of >0.8, obtained over the entire screen of 64,394 compounds (see Fig. 2) , and a confirmation rate of >75% either in single-concentration retests or full doseresponse determinations.
The luminescent assay is very sensitive and allowed >100fold decrease in TNAP concentration and dramatic reduction of phosphoacceptor levels compared to the colorimetric assay while still maintaining maximal sensitivity. The concentrations of CDP-star and DEA substrates were kept equal to their respective K m values to ensure optimal response to inhibitors with different MOA, that is, competitive and uncompetitive against either of the substrate molecules. This is in stark contrast to the utilization of a saturating concentration of phosphoacceptor/buffer (1M DEA) common in the clinical tests for the determination of AP activity in different tissue specimens. 23, 37 
Generation of diverse HTS hit classes
MOA with respect to phosphate-donating substrate. Both competitive and uncompetitive inhibitors with respect to CDPstar substrate were identified. Notably, competitive inhibitors of APs have never been reported prior to this work. The best representatives of competitive TNAP inhibitors, pyrazole and triazole scaffolds, identified in this study have nanomolar potency. We note that competition with a bulky CDP-star substrate does not necessarily mean that the compounds would be competitive with a much smaller inorganic pyrophosphate substrate, 28 so further work to clarify the MOA of these inhibitors with the native substrate pyrophosphate is necessary. Nevertheless, it seems safe to infer that the compounds are much more likely to be competitive with bulkier substrates of TNAP, such as AMP and PLP, than with the smaller PP i . It is also possible that molecules with narrow specificities for targeting diverse natural reactions of TNAP could be identified and/or designed via medicinal chemistry approaches within the CDP-star-competitive series, such as pyrazoles and triazoles. These mechanism-specific compounds may enable differential inhibition of the unique biological activities of TNAP. A common feature of competitive inhibitors is that they are ineffective in the presence of elevated (relative to K m ) concentrations of the corresponding substrate. As a consequence, chemical probes with this attribute could act as sensors of the local concentration of natural substrates of TNAP in a specific biological environment. Similarly, if employed as therapeutic agents, they have the potential to be selective with respect to specific physiological functions of TNAP.
All known-to-date inhibitors of TNAP demonstrated uncompetitive mechanism with respect to phosphate-donating substrates. The biarylsulfonamides identified in the current study are also uncompetitive. However, they represent a significant improvement over the existing state of the art: the best biarylsulfonamide, MLS-0038949, has mid-nanomolar potency, exceeding the µM potencies of levamisole 25 and ChemBridge 5804079 (identified in our earlier screening efforts 20 ) by 2 orders and 1 order of magnitude, respectively.
Compounds uncompetitive with the phosphate-donor substrate, especially as potent as MLS-0038949, would be useful in experiments of the chemical knockdown of TNAP. The ratelimiting step of the TNAP reaction is downstream of the activesite serine phosphorylation and alcohol product release 22 (DOH in Fig. 1) , leading to elevated concentration of phosphoenzyme species in the steady state independent of the nature of substrate. Consequently, uncompetitive inhibitors of TNAP are expected to sustain their mode of action irrespective of the actual phosphate-donating substrates. On the other hand, they are sensitive to the level of saturation with these substrates and thus could act as sensors of the TNAP active-site occupancy within its specific environment.
MOA with respect to phosphate-accepting substrate. The majority of compounds that we identified in the HTS luminescent assay did not inhibit TNAP in the presence of high DEA concentration. Competition with DEA, a phosphate-acceptor substrate, is proposed to explain these observations. For 2 of the scaffolds (pyrazoles and triazoles) that were further characterized, their competition with DEA was confirmed in the MOA studies. TNAP inhibitors competing with DEA were N unknown prior to this study. A possible explanation is that most AP assays performed to date employed a saturating concentration of phosphate-acceptor substrate. 20, 23, 37 Inhibitors competitive with the phosphate-acceptor substrate are poised to serve as valuable research tools to study the transphosphorylation reaction in vivo and to help in the identification of its potential substrates. The DEA molecule is relatively small in size; thus, the compounds competitive with DEA are expected to compete with any other phosphate-acceptor substrates (AOH in Fig. 1) . It is also possible that careful characterization and further medicinal chemistry optimization of the scaffolds identified in this study could furnish the molecules with a spectrum of selectivity for different phosphate-acceptor substrates and thus would result in probes selective to different classes of transphosphorylation substrates.
On the other hand, compounds noncompetitive with DEA are not expected to interfere with the transphosphorylation reaction. They could serve as valuable reference compounds to differentiate between the effects on the phosphate-donor-and phosphate-acceptor-driven stages of the reaction. Two different types of DEAnoncompetitive inhibitors were identified in this study. For example, MLS-0039961 is competitive with the phosphate-donor substrate similar to pyrazoles and triazoles but noncompetitive with the phosphate-acceptor substrate. Conversely, the biarylsulfonamide compounds are uncompetitive with the phosphate-donor and noncompetitive with the phosphate-acceptor substrates. As mentioned above, only 4 primary hits demonstrated activity in the colorimetric assay. One of them was MLS-0039961. Three others were representatives of the biarylsulfonamide scaffold, and all 3 possessed pyridine and o-alkoxybenzene groups connected with a sulfonamide linker (first 3 compounds in Table 2 ). The fourth biarylsulfonamide that lacked the pyridine but contained a triazole moiety instead (compound MLS-0043574 in Table 2 ) is inactive in the colorimetric assay and thus potentially competes with DEA for binding. Perhaps the triazole moiety in this case defines the binding site and thus the MOI of the compound. As a more general conclusion, the triazole moiety of this mixed scaffold may be targeting the binding site occupied by the nitrogen atom of DEA. It would be interesting to see if MLS-0043574 sustained the uncompetitive MOA against CDP-star innate to other biarylsulfonamides or if it adopted the competitive character of other triazoles.
Concluding remarks: TNAP screening campaign as an MLSCN project
The specifics of performing a project within the MLSCN were outlined elsewhere. 32, 38 Carrying out the TNAP screening through the MLSCN Roadmap Initiative brought several essential benefits that were not available otherwise yet were critical for the success of the project. To start with, the cost of a chemical probe identification project, including the assay development, screening, SAR studies, and medicinal chemistry hit optimization, is estimated at several hundreds of thousands of dollars and is prohibitive to an ordinary research laboratory. All the expenses related to the project were covered by the MLSCN U54 grant supporting the operations of the Burnham Center for Chemical Genomics.
The X01 grant mechanism allowed free access to the services and resources available within the MLSCN at no cost to the research lab. Among other resources, the MLSCN compound library is available to the projects performed within the network. The library is assembled, maintained, and supplied by the MLSMR for primary HTS and hit confirmation. As mentioned in Materials and Methods, compounds are selected to represent diversified chemical space with clusters of closely related analogs. Incorporation of multiple analogs within the compound collection provides the basis for rapid HTS-based SAR analysis. As can be seen in this study, this type of HTS data analysis served as a valuable tool for preliminary SAR studies, especially for the biarylsulfonamide scaffold, which contained a large number of compounds.
As mentioned above, the MLSMR supplies compound solutions for both primary HTS and hit confirmation. The fact that most of the compounds in the MLSMR collection originate from commercial sources is a key factor for rapid confirmation of hit efficacy and structures based on commercial compounds. Outstanding reproducibility of the results between the library and the dry-powder commercial compounds (apparent from Table 4 ) attests to the high integrity of the screening compound collection.
The commercial origin of the compounds in the MLSMR collection is a key factor not only for rapid compound confirmation but also for expanding the preliminary SAR. According to the common practice of the chemical supplies industry, most commercial compounds are produced in a series of multiple analogues. Maximizing the number of analogs in a series allows manufacturers to make the best use of their initial investment in the development of novel synthetic routes. This sets a foundation for the commonly used approach of "analoging by cataloging" (ABC), which we successfully used for the confirmation of HTS SAR models and the optimization of the primary hits, as will be reported elsewhere. 31 Another benefit of performing the assay within the MLSCN is the unprecedented amount of selectivity data available for hundreds of thousands of MLSCN compounds. The MLSMR compound collection was supplied to 10 MLSCN centers. The data produced in hundreds of MLSCN-based HTS campaigns are released into the public domain and can be accessed through the PubChem portal maintained by the National Center for Biotechnology Information (NCBI). For example, the representatives of the 3 scaffolds identified in this study were screened in >220 assays (in addition to our own AP isoform selectivity panels), each providing an immense selectivity profiling.
This project exemplifies a highly successful HTS campaign in which a diverse set of chemical probes was identified and developed. To summarize, 3 major scaffolds of TNAP inhibitors were identified. They were characterized with high potency, diverse mode of actions, and extraordinary level of specificity to TNAP. These chemical probes will provide tools for the characterization of the physiological functions and the catalytic mechanism of TNAP. Several hits demonstrate high potency in the TNAP pyrophosphatase activity and are further pursued as starting points for future intervention of soft tissue ossification, as will be reported elsewhere.
